ProCE Banner Activity

Should We Worry About Hepatitis B Core Antibody Before ART Switch?

Conference Coverage
Clinical Thought

Our retrospective study from Western Europe, presented at EACS 2023, suggests we might need to consider anti-HBc.

Released: November 13, 2023

Share

Faculty

Karine Lacombe

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Faculty Disclosure

Primary Author

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Karine Lacombe, MD, PhD: consultant/advisor/speaker: Gilead, Merck Sharp & Dohme, Viiv Healthcare.